StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
NTV-R.BK$19.00+0.00%
Fair $19.00+0.0%

NTV-R.BK

Nonthavej Hospital Public Company Limited

Healthcare / Medical Care FacilitiesThailand

$19.00

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $19.00Fund rank 33/100 · Data gapFallback financials|
SA 29/D
F-Score: 3/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $354.4M · quality 63.7/100

Data gap 33/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 79/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

29/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · NTV-R.BKLocal privado en este navegador · Nonthavej Hospital Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$3.0B

P/E

12.4x

↓

EV/EBITDA

3.7x

↓

ROE

9.8%

↑

Gross Margin

26.9%

↓

Debt/Equity

N/A

•
52-Week Range$19
$22$29

TradingView lightweight chart

NTV-R.BK price, volumen y niveles de valoración

Último $22.00Periodo +84.9%
Fair value: $19.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+1.7%

FCF CAGR

-19.2%

FCF margin

8.4%

FCF / Net income

0.72x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.37B · net income $276.8M · FCF $199.6M

2022-FY → 2025-FY

Gross margin

26.9%-2.2% pts

Operating margin

13.6%-2.8% pts

Net margin

11.7%-1.7% pts

FCF margin

8.4%-8.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$2.37B$2.37B$2.48B$2.47B$2.26B
Net Income$276.8M$276.8M$360.7M$387.7M$300.6M
EBITDA$526.0M$526.0M$620.4M$650.7M$556.7M
EPS1.731.732.252.421.88
Gross Margin26.9%26.9%29.8%30.9%29.1%
Operating Margin13.6%13.6%17.3%19.1%16.4%
Net Margin11.7%11.7%14.5%15.7%13.3%
Balance Sheet
Current Ratio4.204.20———
Cash Flow
Free Cash Flow$199.6M$199.6M$354.4M$406.1M$377.8M
Returns
ROE9.8%9.8%13.1%14.7%12.4%
Valuation
P/E12.4212.4216.8215.6321.64
EV/EBITDA3.673.678.437.939.94
P/B1.081.082.202.302.68
Growth & Yield
Revenue Growth-4.5%-4.5%0.5%9.6%—
EPS Growth-23.1%-23.1%-7.0%28.7%—
Dividend Yield4.7%4.7%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-0.9%

fácil

EPS terminal req.

$1.69

Spread vs growth

-22.3%

5Y implied EPS CAGR

3.4%

fácil

EPS terminal req.

$2.04

Spread vs growth

-26.5%

10Y implied EPS CAGR

6.6%

razonable

EPS terminal req.

$3.29

Spread vs growth

-29.7%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -20.1%

Total return

-20.1%

Start / end P/E

13.0x → 12.7x

EPS bridge

2.25 → 1.73

Residual

+0.5%

EPS growth-23.1%
Multiple rerating-2.2%
Dividend+4.7%
Residual / FX / buybacks / cross-term+0.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.